-
Whitlock JA, Malvar J, Dalla-Pozza L, Goldberg JM, Silverman LB, Ziegler DS, Attarbaschi A, Brown PA, Gardner RA, Gaynon PS, Hutchinson R, Huynh VT, Jeha S, Marcus L, Messinger Y, Schultz KR, Cassar J, Locatelli F, Zwaan CM, Wood BL, Sposto R, Gore L. Nelarabine, etoposide, and cyclophosphamide in relapsed pediatric T-acute lymphoblastic leukemia and T-lymphoblastic lymphoma (study T2008-002 NECTAR). Link to Pediatric Blood Cancer Published: 21 August 2022
-
Eric S. Schafer, Karen Chao, Alexandra M. Stevens, Eunji Jo,Susan G. Hilsenbeck, Nathan P. Gossai, Andrew Doan, Susan I. Colace,Terri Guinipero, Daniel Otterson, Joel A. Kaplan, Ashley Hinson,Lauren Pommert, Alan S Wayne, Deepa Bhojwani, Michael J. Burke Real-world experience in treating pediatric relapsed/refractory or therapy related myeloid malignancies with decitabine, vorinostat, and FLAG therapy based on a phase 1 study run by the TACL consortium. Link to Pediatric Blood and Cancer Published: June 21, 2022
- Lauren Pommert, Eric S. Schafer, Jemily Malvar, Nathan Gossai, Ellynore Florendo, Kirthi Pulakanti, Katelyn Heimbruch, Cary Stelloh, Yueh-Yun Chi, Richard Sposto, Sridhar Rao, Van Thu Huynh, Patrick Brown, Bill H. Chang, Susan I. Colace, Michelle L. Hermiston, Kenneth Heym, Raymond J. Hutchinson, Joel A. Kaplan, Rajen Mody, Tracey A. O’Brien, Andrew E. Place, Peter H. Shaw, David S. Ziegler, Alan Wayne, Deepa Bhojwani, Michael J. Burke Decitabine and Vorinostat with FLAG Chemotherapy in Pediatric Relapsed/Refractory AML: Report from the Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) Consortium Link to American Journal of Hematology Published: Feburary 2022
- Sarah K. Tasian, Lewis B. Silverman, James A. Whitlock, Richard Sposto, Joseph P. Loftus, Eric S. Schafer, Kirk R. Schultz, Raymond J. Hutchinson, Paul S. Gaynon, Etan Orgel, Caroline M. Bateman, Todd M. Cooper, Theodore W. Laetsch, Maria Luisa Sulis, Yueh-Yun Chi, Jemily Malvar, Alan S. Wayne, and Susan R. Rheingold Temsirolimus combined with cyclophosphamide and etoposide for pediatric patients with relapsed/refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium trial (TACL 2014-001) Link to Haematologica Published: Feburary 2022
- Goldberg J, Bender J, Jeha S, Sulis ML, Gardner R, Pollard J, Aquino V, Laetsch T, Winick N, Fu C, Marcus L, Sun W, Verma A, Burke M, Ho P, Manley T, Mody R, Tcheng W, Thomson B, Park J, Sposto R, Messinger Y, Hijiya N, Gaynon P, Barredo J. A phase I study of panobinostat in children with relapsed and refractory hematologic malignancies. Link to Pediatric Hematology and Oncology Published: April 2020
- Burke MJ, Kostadinov R, Sposto R, Gore L, Kelley SM, Rabik C, Trepel JB, Lee M, Yuno A, Lee S, Bhojwani D, Jeha S, Chang BH, Sulis M, Hermiston ML, Gaynon P, Huynh V, Verma A, Gardner R, Heym KM, Dennis RM, Ziegler DS, Laetsch TW, Oesterheld JE, Dubois SG, Pollard JA, Glade-Bender J, Cooper TM, Kaplan JA, Farooqi MS, Yoo B, Guest E, Wayne AS, Brown PA. Decitabine and Vorinostat with Chemotherapy in Relapsed Pediatric Acute Lymphoblastic Leukemia: A TACL Pilot Study. Link to Clinical Cancer Research Published January 2020
- Ronsley R , Kariminia A, Ng B , Mostafavi S, Reid G, Subrt P, Hijiya N , Schultz KR The TLR9 Agonist (GNKG168) Induces a Unique Immune Activation Pattern in Vivo in Children With Minimal Residual Disease Positive Acute Leukemia: Results of the TACL T2009-008 Phase I Study Link to Pediatric Hematology and Oncology Published: Sep 2019
-
Pommert L, Bhojwani D, Sposto R, Florendo E, Schafer E, Gossai N, Huynh VT, Rao S, Burke MJ. Phase 1 study of decitabine and vorinostat followed by fludarabine, cytarabine and G-CSF (FLAG) in children, adolescents and young adults with relapsed/refractory AML: Report from the Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) Consortium. 2019 ASH Oral and Poster Abstracts
- Sun W, Malvar J, Sposto R, Verma A, Wilkes JJ, Dennis R, Heym K, Laetsch TW, Widener M, Rheingold SR, Oesterheld J, Hijiya N, Sulis M, Huynh V, Place AE, Bittencourt H, Hutchinson R, Messinger Y, Chang B, Matloub Y, Ziegler DS, Gardner R, Cooper T, Ceppi F, Hermiston M, Dalla-Pozza L, Schultz KR, Gaynon P, Alan S. Wayne AS, Whitlock JA. Outcome of children with multiply relapsed B-cell acutelymphoblastic leukemia: a therapeutic advances in childhood leukemia & lymphoma study. Link to Leukemia Published March 2018
- Sun W, Triche T Jr., Malvar J, Gaynon P, Sposto R, Yang X, Bittencourt H, Place AE, Messinger Y, Fraser C, Dalla-Pozza L, Salhia B, Jones P, Wayne AS, Gore L, Cooper TM, Liang G. A phase 1 study of azacitidine combined with chemotherapy in childhood leukemia: a report from TACL consortium. Link to Blood Published March 2018
- Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL): Overview and introduction to the proceedings of the 2016 TACL Investigator Meeting Link to Pediatric Hematology and Oncology, Nov 2017
- Cooper TM , Cassar J , Eckroth E , Malvar J , Sposto R, Gaynon P, Chang BH, Gore L , August K, Pollard PA , DuBois SG , Silverman LB , Oesterheld J , Gammon G, Magoon D, Annesley C, Brown PA “A Phase I Study of Quizartinib Combined with Chemotherapy in Relapsed Childhood Leukemia: A Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study” Link to Clinical Cancer Research February 2016
-
A Phase I Dose Finding Study of Panobinostat in Children with Hematologic Malignancies: Initial Report of TACL Study T2009-012 in Children with Acute Leukemia. Link to ASH Abstract in Blood: 124 (21)
-
A Phase 1 Study of Azacitidine (AZA) in Combination with Fludarabine and Cytarabine in Relapse/Refractory Childhood Leukemia: A Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study. Link to ASH Abstract in Blood: 124 (21)
- Invasive Candida Infections in Pediatric Patients Treated on the Pilot Study of Decitabine and Vorinostat with Chemotherapy for Relapsed ALL: A Report from the Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Consortium. Link to ASH Abstract in Blood: 124 (21)
- A phase I study of EZN-3042, a novel survivin messenger ribonucleic acid (mRNA) antagonist, administered in combination with chemotherapy in children with relapsed acute lymphoblastic leukemia (ALL): a report from the therapeutic advances in childhood leukemia and lymphoma (TACL) consortium. Link to: J. Ped Hem Onc Aug-2014
- Results Of a Phase I Study Of Clofarabine and 2 Gy Total Body Irradiation (TBI) As a Non-Myeloablative Preparative Regimen For Hematopoietic Stem Cell Transplantation (HSCT) In High Risk Children With Hematologic Malignancies: A Multi-Center TACL Study. Link to: ASH Abstract Nov-2013
- A Phase I Study of AC220 in Combination with Cytarabine and Etoposide in Relapsed/Refractory Childhood ALL and AML: A Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study. Link to: Link to: ASH Abstract Dec-2013
- Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia: Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study. Link to: Blood May-2012
- Bortezomib Combined with VXLD Chemotherapy Is Highly Effective In Advanced B-Lineage Acute Lymphoblastic Leukemia Allowing Early Study Termination Due to Efficacy. A Therapeutic Advances in Childhood Leukemia (TACL) Consortium Phase II Study. Link to: ASH Abstract Dec-2011
- Outcome for Children Treated for Relapsed or Refractory Acute Myelogenous Leukemia (rAML): A Therapeutic Advances in Childhood Leukemia (TACL) Consortium Study. Link to: Pub Med May-2010
- Phase I study of bortezomib combined with chemotherapy in children with relapsed childhood acute lymphoblastic leukemia (ALL): A report from the therapeutic advances in childhood leukemia (TACL) consortium. Link to: Blood April 2010
- Outcome of Patients Treated for Relapsed or Refractory Acute Lymphoblastic Leukemia: A Therapeutic Advances in Childhood Leukemia Consortium Study. Link to: JCO Oct-2009
- An Adjustment for Patient Heterogeneity in the Design of Two-Stage Phase II Trials. Link to: Statistics in Medicine, June-2009